Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU, Verweij J. Van Cutsem E, et al. Among authors: twelves c. J Clin Oncol. 2000 Mar;18(6):1337-45. doi: 10.1200/JCO.2000.18.6.1337. J Clin Oncol. 2000. PMID: 10715306 Clinical Trial.
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group. Van Cutsem E, et al. Among authors: twelves c. J Clin Oncol. 2001 Nov 1;19(21):4097-106. doi: 10.1200/JCO.2001.19.21.4097. J Clin Oncol. 2001. PMID: 11689577 Clinical Trial.
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P, Schilsky RL; Capecitabine Colorectal Cancer Study Group. Cassidy J, et al. Among authors: twelves c. Ann Oncol. 2002 Apr;13(4):566-75. doi: 10.1093/annonc/mdf089. Ann Oncol. 2002. PMID: 12056707 Free article. Clinical Trial.
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C; X-ACT Study Group. Scheithauer W, et al. Among authors: twelves c. Ann Oncol. 2003 Dec;14(12):1735-43. doi: 10.1093/annonc/mdg500. Ann Oncol. 2003. PMID: 14630678 Free article. Clinical Trial.
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Hénin E, You B, VanCutsem E, Hoff PM, Cassidy J, Twelves C, Zuideveld KP, Sirzen F, Dartois C, Freyer G, Tod M, Girard P. Hénin E, et al. Among authors: twelves c. Clin Pharmacol Ther. 2009 Apr;85(4):418-25. doi: 10.1038/clpt.2008.220. Epub 2008 Dec 10. Clin Pharmacol Ther. 2009. PMID: 19078948 Clinical Trial.
A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.
Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C. Scott L, et al. Among authors: twelves c. Ann Oncol. 2007 Mar;18(3):569-75. doi: 10.1093/annonc/mdl439. Ann Oncol. 2007. PMID: 17322542 Free article. Clinical Trial.
306 results